Clinical trial
A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV
NCT04566770 is registered in ClinicalTrials.gov with CanSino Biologics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo -Controlled Phase IIb Clinical Trial to Evaluate the Safety and Immunogenicity of Ad5-nCoV in Person 6 Years of Age and Older and Those Who Have Previously Been Vaccinated With Ad5-EBOV
- Lead sponsor
- CanSino Biologics Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 24, 2020
- Completion date
- January 19, 2022
- Enrollment
- 480 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.